相关实验视频

Updated: Sep 8, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

在ALK⁺治疗非小细胞肺癌中组织肺炎:一个病例报告

Xiao Lin¹, Mengyao Xie², Dandan Ma¹

¹The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.

Discover oncology

|July 18, 2025

概括

组织性肺炎 (OP) 是ALK抑制剂谢里替尼在非小细胞肺癌 (NSCLC) 患者中罕见的副作用. discontinuing ceritinib and administering steroids effectively treated a patient with this condition. discontinuing ceritinib and administering steroids effectively treated a patient with this condition. discontinuing ceritinib and administering steroids effectively treated a patient with this condition. discontinuing ceritinib and administering steroids effectively treated a patient with this condition. discontinuing ceritinib and administering steroids effectively treated a patient with this condition. discontinuing ceritinib and administering steroids effectively treated a patient with this condition. discontinuing ceritinib and administering steroids effectively treated a patient with this condition. discontinuing 塞里尼布的治疗和使用类固醇有效地治疗了一个患有这种病症的患者,因为他们已经停止使用该药物并开始使用类固醇.

科学领域:

在瘤学瘤学.
肺部病理学肺部病理学
药理学药理学是指药理学的学科.

背景情况:

无细胞淋巴瘤激酶 (ALK) 抑制剂已被批准用于ALK重组的非小细胞肺癌 (NSCLC).
作为ALK抑制剂的利尼布可以引起不良反应,包括组织性肺炎 (OP).
很少有人报告了由塞里尼布诱导的OP病例.

研究的目的:

在患有肺腺癌的患者中报告ALK抑制剂谢里替尼引起的组织性肺炎 (OP) 病例.
要突出诊断的挑战和有效的管理策略,为塞利尼尼布诱导的OP.

主要方法:

一名59岁的女性患有ALK阳性肺腺癌,呈现出持续的咳.
计算机断层扫描 (CT) 引导的肺活检证实了组织性肺炎 (OP).
治疗涉及切尔尼布的停用,甲基前尼索隆的管理,并随后切换到恩萨丁尼布.

主要成果:

最初的抗生素治疗是无效的.
病理诊断证实了组织性肺炎 (OP).
胸部CT显示,在用类固醇治疗和停止使用雪利尼布治疗后,病变已消失.

结论:

组织性肺炎 (OP) 应考虑在出现新的肺病变的NSCLC患者,而不是感染,转移或进展.
病理活检对于准确诊断至关重要.
停止结合类固醇治疗的塞里替尼布疗法在管理塞里替尼布诱导的OP方面被证明是有效的.

关键词:

ALK + ALK + ALK + ALK + ALK + ALK + ALK + ALK + ALK +案例报告案例报告切利尼尼布 (Ceritinib) 的使用方法非小细胞肺癌是非小细胞肺癌.组织肺炎的组织

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...